Revised: 31 May 2019
Medicines
Medsafe Product Detail | ||
---|---|---|
File ref: TT50-5539/1 |
Trade Name | Dose Form | Strength | Identifier |
Potassium chloride 30mmol in 5% Glucose | Solution for infusion | 30 mmol/L | Viaflex |
Sponsor | Application date | Registration situation | Classification |
Baxter Healthcare Ltd P O Box 14062 Panmure AUCKLAND 1741 | 29/9/1980 | Consent given Approval date: 29/9/1980 | General sale |
Composition
Component | Ingredient | Manufacturer |
solution for infusion | Active | |
Glucose 5% | ||
Potassium chloride 0.224% |
Production
Manufacturing step | Manufacturer |
Finished Product Testing | Baxter Healthcare Pty Ltd 1 Baxter Drive Old Toongabbie NSW 2146 AUSTRALIA |
Manufacture of Final Dose Form | Baxter Healthcare Pty Ltd 1 Baxter Drive Old Toongabbie NSW 2146 AUSTRALIA |
Packing | Baxter Healthcare Pty Ltd 1 Baxter Drive Old Toongabbie NSW 2146 AUSTRALIA |
NZ Site of Product Release | Baxter Healthcare Ltd 33 Vestey Drive Mt Wellington AUCKLAND |
Packaging
Package | Contents | Shelf Life |
Bag, plastic, | 1000 mL | 24 months from date of manufacture stored at or below 30°C |
Indications
Potassium chloride and Glucose IV infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of potassium and chloride ion concentrations. This is also an alternative route of administration for patients who are unable to take potassium orally or if hypokalaemia is severe. It may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.
Latest Regulatory Activity
Application Date | Application Type | Change(s) | Status | Payment Date | Priority |
4/7/2023 | Changed Medicine Notification | Finished product specifications/test methods - G2; Administrative fee (CMN) | Granted 3/11/2023 | 29/8/2023 |